pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,950 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1893Endpoints1466Fierce Biotech779BioSpace767BioPharma Dive555raps257onclive165fda recalls126
therapy area
allOncology13097Rare Disease3399Immunology3069Cardiology2869Hematology2336Pulmonology2300Vaccines
  • Kyntra Bio drops mid-stage prostate cancer ADC program after failing efficacy criteria
    Kyntra Bio announced in its third-quarter earnings release that it is terminating the phase 2 study of its CD46-targeting antibody-drug conjugate FG-3246 in metastatic castration-resistant prostate…
    Fierce Biotech · 4d agoNegative↗ source
  • Panelists say 2027 could be Europe’s breakout year for biotech investment
    Fierce Biotech hosted a panel during its London Life Sciences Week to debate whether Europe can boost its biopharma investment in 2027. The discussion came a day after venture capital firm Sofinno…
    Fierce Biotech · 4d agoPositive↗ source
← prev
page 6 of 158
next →
fda medwatch117
globenewswire health73
fda press62
1892
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
EU regulators and industry discuss streamlining combination product oversight at summit
At the AFDO/RAPS Combination Products Summit, a panel of European regulators and industry representatives met to explore ways to simplify the regulatory pathway for combination products in the EU.…
raps · 4d agoRegulatoryNeutral↗ source
  • Heidi Overton faces Senate committee vote on FDA commissioner nomination amid uncertainty
    The Trump administration’s nominee for FDA commissioner, Heidi Overton, is scheduled for a vote before the Senate health, education, labor and pensions committee. Lawmakers have not indicated a cl…
    Endpoints · 3d agoRegulatoryNeutral↗ source
  • Cognito Therapeutics readies FDA submission for Alzheimer's light-and-sound headset after trial miss
    Cognito Therapeutics is preparing an FDA submission for its Spectris device, a headset that delivers patterned light and sound therapy aimed at treating Alzheimer's disease. The technology builds o…
    Endpoints · 3d agoRegulatoryNeutral↗ source
  • Marrow Therapeutics raises $173M to develop simpler alternative to gene therapies for sickle cell and beta thalassemia
    Marrow Therapeutics, a newly announced biotech startup, has secured $173 million in venture funding to pursue a new treatment for severe blood disorders such as sickle cell disease and beta thalass…
    BioPharma Dive · 3d agoDealPositive↗ source
  • FDA releases new manual outlining clinical pharmacology review practices for NDAs and BLAs
    The U.S. Food and Drug Administration’s Office of Translational Sciences and Office of Clinical Pharmacology have issued a new manual of procedures and policies (MAPP).\n\nThe document sets out goo…
    raps · 4d agoRegulatoryNeutral↗ source
  • Larbi Inc. recalls three lots of Yellow Dock Root over possible Salmonella contamination
    Larbi Inc. announced a recall of three lots of its Herb To Body Yellow Dock Root 4-oz product because it may be contaminated with Salmonella. The product was sold nationwide from January to Novemb…
    fda recalls · 3d agoCRLNegative↗ source
  • React Health issues voluntary recall of Luna G3 BPAP devices over data handling error
    React Health (operating as 3B Medical) announced a voluntary correction of certain Luna G3 BPAP System units (model LG3800-30VT) because a data handling issue can produce incorrect therapy pressure…
    fda recalls · 3d agoRegulatoryNegative↗ source
  • Novo revamps NovoCare DTC platform as Roche’s Gazyva receives renewed approval
    Novo announced a revamp of its direct-to-consumer service, NovoCare, describing it as a reimagined platform for patients. The update includes a refreshed user interface and expanded resources aime…
    Endpoints · 3d agoRegulatoryNeutral↗ source
  • b.well introduces safety tools for AI health chatbots
    b.well, a startup focusing on patient data, announced new tools aimed at improving safety of AI-driven health chatbots. The tools address concerns that large language models may mishandle personal…
    Endpoints · 3d agoPositive↗ source
  • Biotech boards see more women, but CEO roles remain largely male-dominated
    Women now occupy roughly 29% of biotech board seats, a notable rise from about one‑fifth a few years ago, according to the latest Bedford Group Transearch report. Despite that progress, female CEO…
    BioSpace · 4d agoNegative↗ source
  • Fresh & Ready Foods expands recall to include additional Fresh to You sausage, egg & cheese biscuit sandwiches over Listeria risk
    Fresh & Ready Foods announced an expansion of its November 8 recall, now covering additional Fresh to You sausage, egg & cheese biscuit sandwiches made at its Longview, Texas facility. The move fo…
    fda recalls · 3d agoCRLNegative↗ source
  • Health tech firms eye consumer-driven future at HLTH conference in Las Vegas
    The Endpoints team attended the HLTH conference in Las Vegas despite a ground stop on Friday, gathering insights on health technology trends. Observations suggest the industry is shifting toward c…
    Endpoints · 3d agoNeutral↗ source
  • FDA to call AI "super intelligence" in all official communications
    The FDA announced that it will replace the term "artificial intelligence" with "super intelligence" in its official materials. The change applies to all correspondence, public communications, webs…
    raps · 4d agoRegulatoryNeutral↗ source
  • Lilly pens another deal, inking up to $5.9B oncology pact with Stipple
    A licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.
    BioSpace · 3d ago↗ source
  • Recon: FDA approves Roche’s oral SERD for late-stage breast cancer; Lilly strikes up to $5.9B cancer deal with Stipple Bio
    Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
    raps · 4d ago↗ source
  • IQVIA report finds 90% of drugs launched 2016-2020 unlikely to recoup costs
    IQVIA analyzed 825 novel medicines launched in the United States between 1991 and 2020 and found that profitability has sharply declined over time. For drugs launched from 2016 to 2020, a positive…
    BioSpace · 4d agoNegative↗ source
  • J&J to acquire Ollin Biosciences for $2.2 billion to advance bispecific eye drug OLN324 against Roche’s Vabysmo
    Johnson & Johnson announced it will buy Ollin Biosciences for an upfront $2.2 billion, with additional regulatory and commercial milestones that could bring total payments to about $3.3 billion. O…
    Fierce Biotech · 5d agoDealPositive↗ source
  • Eli Lilly inks up to $5.9 billion partnership with Stipple Bio to develop cancer therapies
    Eli Lilly announced a new collaboration with Cambridge-based biotech Stipple Bio, valued at up to $5.9 billion, aimed at creating novel cancer medicines. The agreement gives Lilly access to Stippl…
    Endpoints · 4d agoDealPositive↗ source
  • Helus Pharma reports Phase 3 depression trial shows symptom improvement but safety concerns linger
    Helus Pharma, a psychedelics-focused company, announced results of its Phase 3 trial for its lead depression drug. The trial showed the drug produced greater improvement in depression symptoms com…
    Endpoints · 4d agoPositive readoutNegative↗ source
  • CG Oncology’s cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 trial
    CG Oncology reported that its experimental therapy, cretostimogene, achieved a 68% relative reduction in bladder cancer recurrence in a Phase 3 study of patients who had surgery for non‑muscle inva…
    BioPharma Dive · 4d agoPositive readoutPositive↗ source
  • Novo’s CagriSema shows over 20% weight loss at low doses in Phase 3 trial
    Novo Nordisk presented new Phase 3 data on its experimental obesity combo CagriSema at ObesityWeek 2026. The low‑dose arm (1 mg and 1.7 mg weekly) achieved average weight reductions of about 21% a…
    BioSpace · 4d agoPositive readoutPositive↗ source
  • Helus Pharma's modified psilocybin meets primary and secondary goals in phase 3 depression trial
    Helus Pharma reported that its oral, chemically modified psilocybin candidate, HLP003, was tested in a phase 3 study of 222 patients with major depressive disorder. Participants received a single 1…
    Fierce Biotech · 5d agoPositive readoutPositive↗ source
  • Eli Lilly acquires Calytrix Bio in $1.5 billion deal to add myelofibrosis antibody to its pipeline
    Eli Lilly announced a $1.5 billion acquisition of Massachusetts‑based Calytrix Bio, gaining access to the company’s biparatopic antibody aimed at mutant calreticulin‑driven essential thrombocythemi…
    Fierce Biotech · 5d agoDealPositive↗ source